💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider. The Company is principally engaged in generic finished dosage forms (FDF), Oncology formulations and research and development services to cater to the needs of the…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A middling, stagnant business, trading cheap versus its own history — but flagged on governance.
Medicamen Biotech is scored on the pharma / healthcare framework. It keeps a slim 4.9% of every rupee of sales as net profit. Cash conversion lags the reported profit (CFO/PAT -3.38×) — worth a closer look. Free cash flow is worth about -9.3% of its market value.
Over the last 3 years revenue compounded at 12%/yr and profit at -13%/yr. Book value has grown 13%/yr. Return on equity is a weak 3.5%. In the latest quarter profit fell 58% versus the prior quarter.
At 38× earnings, the stock sits at the 14th percentile of its own 3.6-year range — the cheap end of where it has historically traded. Today's price implies ~18%/yr earnings growth for a decade. The forensic screen raises a red flag: Only ₹-1.34 of cash per ₹1 profit over 4 years — earnings not converting to cash.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 38.57 | — | — |
| P/B | 1.32 | 4.1 | better |
| EV/EBITDA | 16.98 | 19.33 | better |
| ROE | 3.5 | — | — |
| ROCE | 4.79 | 14.41 | worse |
| ROA | 2.7 | 1.64 | better |
| Quick Ratio | 1.75 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
12% CAGR over 3 years — steady double-digit compounder. Growth is accelerating — latest year outpaced the prior year's rate.
Revenue is outpacing profit (12% vs -13%) — costs are rising faster than the top line. The latest year saw a +49% swing — check if it's a one-off or structural.
Operating margin has compressed from 12% to 6% — costs or competition are eating into profitability. Margins have declined for 2 consecutive years — watch for a structural cost problem.
ROE at 4% — modest; the capital isn't working hard.
Profit grew faster than EPS (-13% vs -15%) — share dilution is eroding per-share value. -15% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
4 of 4 years had negative operating cash flow — profitability on paper may not translate to cash. Investing outflows exceed operating cash — the company relies on external funding to finance expansion.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue fell 22% QoQ — could be seasonality or a genuine slowdown. Run-rate stepping up — recent quarters average 17% above earlier ones.
Profit fell 58% QoQ — one-quarter drops can be noise, but a pattern matters.
How today's P/E compares to the stock's own historical range. Dashed line = the 3.6y median.
Promoters at 42.6% — dispersed ownership; institutional flows drive the stock. Promoters added 2.1pp over 4 quarters — creeping acquisition signals conviction. FII stake up 4.3pp over 4 quarters — growing foreign interest.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.